The GT1708F project has been approved for clinical trials in China

(Summary description)

The GT1708F project has been approved for clinical trials in China

(Summary description)

Information
SMO Antagonist Obtains Approval of Clinical Trial from FDA
Kintor Pharmaceutical’s Suzhou Industrialisation Base Granted Approval of Pharmaceutical Production License
Strategic Cooperation Agreement on Biological Drug Development between Kintor Pharmaceutical and Pumis 
Kintor Pharmaceutical Signs Strategic Cooperation Agreement with MabPlex 
Three Parties Jointly Build A Precise Cancer Treatment Platform
New Start For New Journey! Kintor Relocated To Suzhou R&D Center And Industrialization Base
Kintor Pharmaceutical and Gensun Biopharma Announce Exclusive Cooperation on Dual-Targeting Antibody PD-L1/TGF-β in Greater China 
Kintor Pharmaceutical and Alphamab Oncology Announce Partnership to Develop Combination Therapy of GT90001 and KN046
Kintor Pharmaceutical Signs Strategic Cooperation Agreement with JD Pharmacy
Officially listed on the Hong Kong Stock Exchange (Stock Code:9939.HK)
Kintor pharmaceutical and Sinopharm signed a strategic cooperation agreement
The GT1708F project has been approved for clinical trials in China

Scan the QR code to read on your phone